Terapistyring af perfenazinbehandling ved paranoide tilstande. 2. Kliniske aspekter
| Autor: | Kjeldsen, C. S., Larsen, N. E., Kragh-Sørensen, P., Andersen, E., Kim Brosen, Gerholt, F., Glue, P., Mogens Hørder, Klitgaard, N. A., Krarup, G. |
|---|---|
| Jazyk: | dánština |
| Rok vydání: | 1991 |
| Zdroj: | Kjeldsen, C S, Larsen, N E, Kragh-Sørensen, P, Andersen, E, Brøsen, K, Gerholt, F, Glue, P, Hørder, M, Klitgaard, N A & Krarup, G 1991, ' Terapistyring af perfenazinbehandling ved paranoide tilstande. 2. Kliniske aspekter. ', Ugeskrift for Laeger, bind 153, nr. 34, s. 2339-2343 . University of Southern Denmark |
| Popis: | Rational use of serum concentration monitoring of the neuroleptic, perphenazine, was evaluated in a prospective investigation. A total of 141 hospitalized patients with paranoid symptoms (excluding mania) requiring treatment were included during the investigation period (one year). Perphenazine was administered (fixed doses) orally (92 patients) and parenterally (depot, decanoate, 45 patients) in a six-week treatment period. Serum concentrations of perphenazine were monitored after 10-14 days oral treatment, on the 14th and 21st days after the commencement of depot treatment. The patients were steered on to the recommended therapeutic range for perphenazine (1.5-6 nmol), according to the serum level measured. Global clinical assessment was carried out by the departmental physicians. Therapy control of perphenazine by serum monitoring was an important supplement to the clinical evaluation of therapeutic effect. Fifteen (65%) out of 23 patients who were treated orally with insufficient therapeutic effect, showed non-compliance or elevated metabolism. On the basis of a single serum concentration measurements (12 hours values), it proved possible to steer the majority of patients onto the recommended therapeutic level. In this way, the individual patient reached optimal therapeutic effect with a minimum of side-effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|